Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

U.S. prescription drug spending to hit $400 billion a year by 2020: IMS

U.S. annual spending on prescription medicines will increase 22 percent over the next five years, climbing as high as $400 billion in 2020, according to a report released by IMS Health.

Read More »

U.S. spends $3 billion a year on unused cancer drugs

U.S. doctors and hospitals throw out almost $3 billion (roughly 2.7 billion euros) in unused cancer drugs each year because the medicines come in supersized single-use packages and excess medicine must be discarded for safety reasons, a recent paper suggests. Researchers focused on 20 expensive medicines that are given by injection or intravenous drip and […]

Read More »

UK cost agency backs J&J cancer drug in change of heart

A cancer drug originally discovered in Britain has finally been endorsed for treating advanced prostate cancer before chemotherapy on the country’s state health service in a change of heart by the cost agency NICE.

Read More »

Express Scripts says U.S. drug spending rose 5.2 percent in 2015

U.S. spending on prescription drugs rose 5.2 percent in 2015 – including the impact of rebates – driven by an 18 percent increase in specialty drugs, Express Scripts Holding Co. said.

Read More »

NY attorney general to investigate insurers over hepatitis C drugs

New York state Attorney General Eric Schneiderman’s office has asked 16 health insurers for documentation on patients who have been denied coverage of drugs used to cure hepatitis C, a person familiar with the matter told Reuters on Wednesday. Schneiderman’s office also requested details on procedures followed by the companies to authorize the drugs used […]

Read More »

UK cost agency rejects leukemia drug from J&J and AbbVie

A new leukemia drug viewed by industry experts as a future blockbuster has been rejected by Britain’s healthcare cost-effectiveness agency NICE, which said it could not be confident the medicine represented an effective use of resources. Imbruvica has a list price of 55,954.50 pounds ($78,000) a year, although it is being offered at an undisclosed […]

Read More »

AstraZeneca sells drug for $70 million as divestment drive continues

AstraZeneca has sold rights to a non-core drug to a unit of Kyowa Hakko Kirin for an upfront payment of $70 million, a day after getting $500 million for two ageing heart medicines.   The British-based drugmaker has been divesting peripheral products to help pay the bills as it invests in new medicines, while taking […]

Read More »

For Clinical Trials, Centralized Imaging Data Collection and Review Is a Must

  By Joseph Pierro, chief medical officer of Biomedical Systems.   In many clinical trials, clinical imaging plays an important role in the drug development process. Whether the trial involves drugs, biologics, or devices, imaging may be used to measure the efficacy and safety of the investigational product. An independent assessment based on the centralized […]

Read More »

China to consolidate drug market, promote traditional medicines

China plans to consolidate its huge and fragmented drug market and will support a greater role for traditional Chinese medicines (TCM), the central government said in a statement on Sunday following a meeting of the State Council.   China will also strengthen safety controls and traceability of domestic drugs, the statement said, part of an […]

Read More »

2016 Annual Report: Top 10 Pipelines

The pharma industry’s R&D concentration has been shifting towards specialty therapy areas as research and development returns decline for some leaders.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2018 Focus: Top 50 Pharma, Company of the Year and more!

Subscribe

Ad Right Bottom